Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytomx Thera 151 OYSTER POINT BLVD.SUITE 400 SOUTH SAN FRANCISCO CA 94080 USA

www.cytomx.com P: 650-515-3185 F: 650-351-0353

Description:

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 116,099
Enterprise Value, $K 103,519
Shares Outstanding, K 77,919
Annual Sales, $ 101,210 K
Annual Net Income, $ -570 K
Last Quarter Sales, $ 41,460 K
Last Quarter Net Income, $ 13,790 K
EBIT, $ 10,820 K
EBITDA, $ 5,580 K
60-Month Beta 1.14
% of Insider Shareholders 7.00%
% of Institutional Shareholders 67.77%
Float, K 72,465
% Float 93.00%
Short Volume Ratio 0.35

Growth:

1-Year Return -12.57%
3-Year Return -79.67%
5-Year Return -86.67%
5-Year Revenue Growth 70.10%
5-Year Earnings Growth 99.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.17 on 05/08/24
Next Earnings Date N/A
Earnings Per Share ttm 0.20
EPS Growth vs. Prev Qtr 1,600.00%
EPS Growth vs. Prev Year 440.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CTMX Ratios

Ratio
Price/Earnings ttm 7.45
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.70%
Return-on-Assets % 8.10%
Profit Margin % -0.56%
Debt/Equity 0.00
Price/Sales 1.15
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.46
Interest Coverage -1.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar